News

Tuesday 28th November 2023

Sharing Data to Improve Lives: The SRUK Patient Registry Survey

SRUK is developing a Patient Registry, with the aim of improving outcomes for people diagnosed with Scleroderma or Raynaud's. Our Registry will be a secure, anonymous database, containing health information about people living with the conditions. It will be used to improve our understanding of Scleroderma and Raynaud's and how different people are affected over time, to help accelerate research into new and better treatments designed to improve quality of life. Read on to find out what we learned through the SRUK Patient Registry Survey, and how it will help shape our Patient Registry.

Read Article

Tuesday 29th November 2022

New study could help find a treatment for scleroderma-related fibrosis

Do you have diffuse systemic sclerosis and live in the UK? Read on to find out how you could take part in a new study which could inform a clinical trial of a new treatment!

Read Article

Monday 21st November 2022

Treating Fibrosis in Scleroderma: SRUK-funded study lays groundwork for potential new treatment for scleroderma-related skin fibrosis

A recently completed study funded by SRUK in 2018, led by Professor Richard Stratton at the Royal Free Hospital, has laid the groundwork for a potential new treatment for scleroderma-related skin fibrosis, which could enable effective and painless treatment of fibrosis in people living with scleroderma.

Read Article

Tuesday 30th November 2021

RAIRDA survey findings on access to third dose

RAIRDA and its member charities are calling for urgent government action to address concerns about the roll-out of third primary doses for the COVID-19 vaccine.

Read Article

Tuesday 30th November 2021

Omicron - The Latest COVID-19 Variant: Should I be Worried?

A new COVID-19 variant originating from South Africa is making headlines due to its large number of mutations and the risk they pose. Designated as a ‘variant of concern’ by WHO, how worried do we need to be about the Omicron variant, and what do you need to be aware of?

Read Article

Thursday 4th November 2021

First take at home COVID-19 antiviral treatments approved for vulnerable adults

Yesterday, the UK’s Medicine and Health products Regulation Agency approved the world’s first ‘take at home’ COVID-19 treatment, Lagevrio – one of two antiviral treatments secured by the UK Government in October.

Read Article

Tuesday 5th November 2019

Research into gut involvement in systemic sclerosis

Dr Tracey Frech, the director of the systemic sclerosis (SSc) clinic at the University of Utah, and Salt Lake Veterans Affair Medical Centre, focussed her talk at the Cambridge conference on gut involvement in systemic sclerosis and the importance of research in this subject area.

Read Article

Friday 30th November 2018

Enhanced Liver Fibrosis Test: A new biomarker of fibrosis in systemic sclerosis

A multicentre study spread across Europe was recently conducted to evaluate how effective the Enhanced Liver Fibrosis (ELF) Test would be as a biomarker of fibrosis (scarring) in systemic sclerosis (SSc).This would aid the understanding of what drives fibrosis in individuals and thus enable the application of precision medicine for treatment strategies.

Read Article

Thursday 8th November 2018

Is gastroesophageal reflux contributing to lung scarring?

A research collaboration between the Royal Free and Royal Brompton hospitals, funded by Scleroderma and Raynaud’s UK (SRUK), is investigating if reflux from the stomach into the oesophagus plays a role in lung scarring in scleroderma patients.

Read Article

Tuesday 6th November 2018

Is there a link between Localised and Systemic Scleroderma?

Keloid morphea is a rare, and hence poorly understood, form of localised scleroderma that only affects the skin. A new study into the condition has the potential to make a huge beneficial impact on our community.

Read Article